Immutep vs Jaguar Health
IMMP and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMMP and JAGX compare
Jaguar Health grew revenue faster over the last twelve months (136% versus 134% for Immutep).
Immutep scores higher on the StockData Score (8 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMMP | JAGX |
|---|---|---|
| Size and price | ||
| Market cap | – | $2.1M |
| Share price | $3.48 | $0.400 |
| Change, 1 year | −90.3% | −100.0% |
| Change, 5 years | −95.4% | −100% |
| Beta (5Y) | 1.67 | 2.17 |
| Employees | 46 | 47 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.1× |
| Growth | ||
| Revenue growth (TTM) | 134% | 136% (better) |
| Revenue growth, 5Y average | 43.5% (better) | 4.2% |
| Profitability | ||
| Gross margin | – | 82.3% |
| Operating margin | – | −93.1% |
| Net margin | −328% | – |
| FCF margin | −230% | – |
| Return on equity | −77.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −25.9× |
| Current ratio | 5.69 (better) | 0.69 |
| Altman Z-score | – | −18.45 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by insiders | 0.89% | 17.1% |
| Short interest, % of float | – | 4.7% |
Go deeper
- IMMP stock overview
- IMMP income statement
- IMMP valuation and score
- JAGX stock overview
- JAGX income statement
- JAGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.